Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries 2seventy bio, Inc. - Common Stock (NQ: TSVT ) 4.470 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about 2seventy bio, Inc. - Common Stock < Previous 1 2 3 4 5 6 Next > 3 Hidden Stock Gems That Wall Street Is Overlooking July 05, 2024 If you play the long game and have a suitable risk tolerance, you can find overlooked stock gems like these three. Via InvestorPlace Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma June 27, 2024 2seventy Bio finalized an asset purchase agreement with Novo Nordisk involving the Hemophilia A program and in vivo gene editing technology. The 2seventy bio team will join Novo Nordisk, focusing on... Via Benzinga 2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million June 26, 2024 From 2seventy bio, Inc. Via Business Wire 2seventy bio to Participate in Upcoming Investor Conferences May 23, 2024 From 2seventy bio, Inc. Via Business Wire A Preview Of 2seventy bio's Earnings March 04, 2024 Via Benzinga TSVT Stock Earnings: 2seventy bio Meets EPS, Misses Revenue for Q1 2024 May 08, 2024 TSVT stock results show that 2seventy bio met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace 2seventy bio Reports First Quarter Financial Results and Recent Operational Progress May 08, 2024 From 2seventy bio, Inc. Via Business Wire 2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024 May 03, 2024 From 2seventy bio, Inc. Via Business Wire FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies April 19, 2024 Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel Via Benzinga Exposures Product Safety FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer April 05, 2024 FDA approves Bristol-Myers Squibb and 2seventy Bio Abecma (ide-cel) for relapsed or refractory multiple myeloma after ≥2 prior therapies. Extends progression-free survival by 13.3 months vs. standard... Via Benzinga Exposures Product Safety U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy April 05, 2024 From Bristol Myers Squibb Via Business Wire 2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron April 01, 2024 From 2seventy bio, Inc. Via Business Wire 2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors March 20, 2024 From 2seventy bio, Inc. Via Business Wire Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session March 18, 2024 Shares of Science Applications International Corporation (NYSE: SAIC) fell sharply during Monday’s session after the company reported financial fourth-quarter EPS below estimates. Via Benzinga FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer March 18, 2024 FDA's adcomm recommends expanded use of Bristol Myers Squibb's Abecma for triple-class exposed relapsed or refractory multiple myeloma, based on Phase 3 study results. Positive vote for Johnson &... Via Benzinga Exposures Product Safety 12 Health Care Stocks Moving In Monday's Pre-Market Session March 18, 2024 Via Benzinga Why Nuvei Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket March 18, 2024 Shares of Nuvei Corp (NASDAQ: NVEI) rose sharply in today’s pre-market trading following a report indicating the company is in buyout talks with Advent International. Nuvei shares jumped 14.1% to... Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday March 18, 2024 Pre-market stock movers are the perfect way to start the week as we dive into the biggest stories moving shares on Monday! Via InvestorPlace FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy March 15, 2024 From Bristol Myers Squibb Via Business Wire Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket March 15, 2024 Shares of Cardlytics, Inc. (NASDAQ: CDLX) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter earnings. Via Benzinga Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley March 07, 2024 Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales. Via Benzinga TSVT Stock Earnings: 2seventy bio Misses EPS, Misses Revenue for Q4 2023 March 05, 2024 TSVT stock results show that 2seventy bio missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. Via InvestorPlace 2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress March 05, 2024 From 2seventy bio, Inc. Via Business Wire 2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences March 01, 2024 From 2seventy bio, Inc. Via Business Wire Earnings Scheduled For March 5, 2024 March 05, 2024 Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion. Via Benzinga Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise February 27, 2024 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining... Via Newsfile 2seventy bio to Participate in Upcoming Investor Conferences February 05, 2024 From 2seventy bio, Inc. Via Business Wire Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study February 05, 2024 From Bristol Myers Squibb Via Business Wire Why Is Sanofi Partner Regeneron Pharmaceuticals Stock Trading Higher Today? February 02, 2024 Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $11.86, down 6% Y/Y, beating the consensus of $10.77. Via Benzinga Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session January 31, 2024 Shares of Advanced Micro Devices, Inc. (NASDAQ: AMD) shares declined 3.8% to $165.49 following fourth-quarter results. AMD reported fourth-quarter non-GAAP earnings per share of 77 cents per share on... Via Benzinga < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.